FCF has committed $631,164 to three projects addressing critical gaps in FA cancer research. The work spans different stages, from exploring oral gene therapy and screening drugs for FA-specific safety to analyzing clinical experiences that could inform future care. These projects are building the knowledge needed to pursue safer cancer options for people with FA.
A Beacon of Support
Fanconi Cancer Foundation
Our mission is to improve the lives of people affected by Fanconi anemia and associated cancers worldwide by funding exceptional research and empowering our community.
Founded in 1989 by parents Lynn and David Frohnmayer, FCF’s contributions have been instrumental in understanding the disease and improving treatments, with more than $33 million funded for 260+ research projects worldwide. Life expectancy has more than doubled as treatments have drastically improved. We must now take on the most significant and currently unsolved problem facing the FA community today: cancer.

